Copyright © Inderes 2011 - present. All rights reserved.
Log ind for at modtage meddelelser.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Moberg Pharma

8,14

 

SEK

 

+7,81 %

Mindre end 1K følgere

MOB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+7,81%
+15,05%
-4,24%
-19,96%
-47,69%
-70,78%
-47,26%
-89,33%
-86,38%

Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.

Læs mere
Markedsværdi
389,74 mio. SEK
Aktieomsætning
1,72 mio. SEK
Omsætning
9,81 mio.
EBIT %
-3.311,21 %
P/E
-
Udbytteafkast, %
-
Finanskalender
22.5
2025

Generalforsamling '25

12.8
2025

Delårsrapport Q2'25

11.11
2025

Delårsrapport Q3'25

Alle
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelsefor 19 timer siden

Redeye: Moberg Pharma Q1 - In the midst of the high season

Moberg Pharma
Selskabsmeddelelsei går

Moberg Pharma interim report January - March 2025

Moberg Pharma
Selskabsmeddelelse22.4.2025, 06.00

Notice of Annual General Meeting in Moberg Pharma AB (publ)

Moberg Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse11.4.2025, 06.00

Moberg Pharma's Annual report for 2024

Moberg Pharma
Pressemeddelelse12.2.2025, 09.37

Redeye: Moberg Pharma Q4’2024 - All eyes on the European market

Moberg Pharma
Selskabsmeddelelse11.2.2025, 07.00

Moberg Pharma Year-end report 2024

Moberg Pharma
Pressemeddelelse3.2.2025, 07.00

Moberg Pharma: Terclara (MOB-015) is now being launched in Norway

Moberg Pharma
Selskabsmeddelelse18.12.2024, 07.00

Moberg Pharma: New terbinafine supplier secured

Moberg Pharma
Selskabsmeddelelse10.12.2024, 19.30

Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU

Moberg Pharma
Pressemeddelelse13.11.2024, 16.55

Redeye: Moberg Pharma Q3’2024 - Launch in focus awaiting top line data

Moberg Pharma
Selskabsmeddelelse12.11.2024, 07.00

Moberg Pharma's Interim report January - September 2024

Moberg Pharma
Selskabsmeddelelse8.11.2024, 07.30

Moberg Pharma's Nomination Committee appointed

Moberg Pharma
Selskabsmeddelelse13.9.2024, 06.00

Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients

Moberg Pharma
Pressemeddelelse14.8.2024, 06.38

Redeye: Moberg Pharma - The Swedish market leader

Moberg Pharma
Selskabsmeddelelse13.8.2024, 06.00

Moberg Pharma's interim report January - June 2024

Moberg Pharma
Selskabsmeddelelse31.7.2024, 06.00

New number of shares and votes in Moberg Pharma AB (publ)

Moberg Pharma
Selskabsmeddelelse28.6.2024, 06.00

New number of shares and votes in Moberg Pharma AB (publ)

Moberg Pharma
Selskabsmeddelelse24.6.2024, 15.35

Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%

Moberg Pharma
Selskabsmeddelelse17.6.2024, 06.00

The last day for trading in Moberg Pharma's warrants of series 2023:1 (TO 2) is today, June 17[th], 2024

Moberg Pharma
Selskabsmeddelelse11.6.2024, 05.30

Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge

Moberg Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team